2025年美国甲状腺协会成人分化型甲状腺癌管理指南
该指南由美国甲状腺协会(ATA)制定,基于系统文献综述(最终检索日期2024年7月1日)和改良GRADE方法,为成人分化型甲状腺癌(DTC)患者提供从诊断、分期、风险评 估、初始治疗、疗效评估、监测到后续治疗的循证推荐,并强调患者报告结局和未来研究方向。
要点
- 指南覆盖DTC全程管理,从诊断到后续治疗。
- 推荐基于系统综述和改良GRADE证据分级。
- 强调患者报告结局和需进一步研究领域。
核心结论
- 修订的循证推荐反映不断发展的科学,优化DTC患者全程的循证临床照护。
研究设计与样本
- ATA多学科专家组进行系统文献综述(最终检索2024年7月1日),并委托两项额外系统综述,采用改良GRADE系统评估证据质量和推荐强度。
关键数值与推荐
- 指南从初始癌症诊断开始,提供分期和风险评估、初始治疗决策、治疗反应评估、监测方法、诊断测试和后续治疗的推荐。
临床怎么用
- 临床医生可依据指南进行DTC患者的诊断、分期、治疗决策和随访监测。
局限性
- 指南强调需额外高质量研究的关键领域,但未具体列出。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: Differentiated thyroid cancer (DTC) is the most prevalent cancer of thyroid and is among the most frequently diagnosed cancers in the United States. The practice guidelines of the American Thyroid Association (ATA) for DTC management in adult patients (previously combined with thyroid nodules) were published initially in 1996, with subsequent revisions based on advances in the field. The goal of this update is to provide clinicians, patients, researchers, and those involved in health policy with rigorous, comprehensive, and contemporary guidelines to assist in the management of adult patients with DTC, emphasizing the patient journey beginning with a thyroid cancer diagnosis. Methods: The questions addressed were based, in part, on prior versions of the guidelines, with input from a larger, more diverse complement of stakeholders. The panel included members from multiple specialties involved in thyroid cancer care, including a patient advocate and an expert in systematic reviews/meta-analyses/guidelines who educated and supported task force members. The panel conducted systematic literature reviews to inform the recommendations and commissioned two additional systematic reviews. Published English-language articles were eligible for inclusion, with a final search date of July 1, 2024. A modified Grading of Recommendations Assessment, Development and Evaluation system was used for critical appraisal of evidence and determining the quality of data. The guidelines panel had editorial independence from the ATA. Competing interests of task force members were pre-vetted, regularly updated, communicated with task force members, and assessed and managed by ATA leadership and the Clinical Practice Guidelines and Statements Committee. Results: These revised guidelines begin with the initial cancer diagnosis and continue with recommendations for staging and risk assessment, initial treatment decisions, assessment of treatment responses, monitoring approaches, diagnostic testing, and subsequent therapies based on the strength of evidence for response and consideration of side effects and outcomes. Patient-reported outcomes and identified areas of need for additional high-quality research are highlighted. Conclusions: These revised evidence-based recommendations inform clinical decision-making in the management of DTC that reflect the changing science and optimize the evidence-based clinical care of patients throughout their journey with DTC. Critical areas of need for additional research are highlighted.
引用
- Ringel MD, Sosa JA, Baloch Z, et al. 2025 American Thyroid Association Management Guidelines for Adult Patients with Differentiated Thyroid Cancer. Thyroid. 2025. PMID: 40844370. doi:10.1177/10507256251363120
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。